Supernus Pharmaceuticals, Inc. (SUPN) Q2 2017 Earnings Results

Supernus Pharmaceuticals Beats on EPS, Stock Up 0.37%

Supernus Pharmaceuticals reported a strong earnings per share figure, exceeding expectations by nearly 27%. The stock reacted positively, gaining 0.37% in response to the earnings beat. However, the absence of revenue details and future guidance may leave investors cautious moving forward.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.32	N/A	+26.77%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a positive outlook regarding their earnings performance. However, the lack of revenue guidance leaves some uncertainty.

Management expressed satisfaction with the EPS performance despite not providing revenue figures.

They highlighted ongoing efforts to enhance product offerings and market presence.

Supernus Pharmaceuticals Beats on EPS, Stock Up 0.37%

Key numbers

Management commentary

Supernus Pharmaceuticals, Inc.

More earnings this week

Supernus Pharmaceuticals Beats on EPS, Stock Up 0.37%

Key numbers

Management commentary